Turku BioImaging in a leading role in the pan-European research infrastructure Euro-BioImaging

The ESFRI research infrastructure Euro-BioImaging (EuBI) is a pan-European infrastructure project for imaging technologies in biological and medical sciences with a mission to provide open user access to a complete range of state-of-the-art imaging technologies in biological, molecular, and medical imaging for life scientists across Europe. The EuBI infrastructure consists of a set of complementary, […]

Turku PET Centre – One of the Best in the World

Turku PET Centre produces an exceptionally wide range of radiopharmaceuticals on a worldwide scale. In a unique way, the centre can both examine individual patients’ diseases and advance medical research. The national Turku PET Centre is jointly run by the University of Turku, Åbo Akademi and the Hospital District of Southwest Finland and is situated […]

Nobel prize winning microscopy in Turku BioImaging

The University of Turku Doctor Honoris Causa Stefan W. Hell was one of the three recipients of the Nobel Prize in Chemistry in 2014. The Prize was awarded to Eric Betzig, William E. Moerner and Hell for groundbreaking work in developing high resolution microscopy. This work for Stefan Hell began in Turku. Stefan W. Hell […]

Universities to Start Collaboration with BIOCAD

Global biotechnological company BIOCAD expands its operations to Finland. The company will establish a production line in Turku and begin collaboration with the University of Turku and Åbo Akademi University. The partner program covers collaboration in education, fundamental sciences and commercial manufacturing. Total investment over 7 years will exceed €25 million. BIOCAD is a global […]

Pharmaceutical Company MSD and Health Campus Turku Signed a Framework Agreement

Collaboration Strengthens Turku’s Position as International Cluster of Expertise in Life Sciences The City of Turku, Hospital District of Southwest Finland, the University of Turku and Åbo Akademi University have made a framework agreement with MSD, one of the biggest pharmaceutical companies in the world. The aim is to create new operational models and modes […]